32.20
0.89%
-0.2221
Schlusskurs vom Vortag:
$32.42
Offen:
$32.57
24-Stunden-Volumen:
3,176
Relative Volume:
0.01
Marktkapitalisierung:
$1.62B
Einnahmen:
$345.60M
Nettoeinkommen (Verlust:
$-79.01M
KGV:
-25.11
EPS:
-1.2822
Netto-Cashflow:
$-18.62M
1W Leistung:
-1.50%
1M Leistung:
-3.54%
6M Leistung:
-37.00%
1J Leistung:
-28.84%
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Firmenname
Immunocore Holdings Plc Adr
Sektor
Branche
Telefon
01235 5430281
Adresse
90 PARK DRIVE, OXFORDSHIRE
Vergleichen Sie IMCR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
IMCR | 32.20 | 1.62B | 345.60M | -79.01M | -18.62M | -1.2822 |
VRTX | 447.51 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.90 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.12 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.20 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-10-31 | Eingeleitet | Robert W. Baird | Outperform |
2023-09-13 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-09-13 | Eingeleitet | Needham | Buy |
2023-08-16 | Eingeleitet | CapitalOne | Overweight |
2023-07-17 | Eingeleitet | Canaccord Genuity | Hold |
2023-03-31 | Eingeleitet | Mizuho | Buy |
2023-03-30 | Eingeleitet | Guggenheim | Buy |
2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
2022-12-16 | Hochstufung | Goldman | Neutral → Buy |
2022-11-30 | Eingeleitet | Barclays | Overweight |
2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
2022-09-08 | Eingeleitet | Ladenburg Thalmann | Buy |
2022-08-08 | Eingeleitet | Cowen | Outperform |
2022-08-02 | Eingeleitet | BTIG Research | Buy |
2022-02-08 | Eingeleitet | H.C. Wainwright | Buy |
2021-10-20 | Eingeleitet | Oppenheimer | Outperform |
2021-03-02 | Eingeleitet | Goldman | Neutral |
2021-03-02 | Eingeleitet | JP Morgan | Overweight |
2021-03-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immunocore Holdings Plc Adr Aktie (IMCR) Neueste Nachrichten
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Barchart
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Nasdaq
Immunocore (IMCR) Upgraded to Buy: Here's Why - MSN
Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India
FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - Barchart
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - Barchart
Mizuho downgrades Immunocore stock to Neutral, slashes PT to $38 from $72 - Investing.com
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
3 Fast-Growing Stocks Analysts See Doubling In Price - Barchart
Immunocore repays Pharmakon loan, ends agreement - Investing.com India
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Barchart
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - Yahoo Finance
Immunocore Holdings earnings beat by $0.50, revenue topped estimates - Investing.com India
Immunocore stock hits 52-week low at $29.72 amid market challenges - Investing.com
Immunocore's SWOT analysis: biotech stock poised for growth amid clinical trials - Investing.com UK
Financial Fitness Check: Examining Immunocore Holdings plc ADR (IMCR)’s Key Ratios - The Dwinnex
Immunocore stock hits 52-week low at $32.07 amid market challenges - Investing.com
TD Cowen maintains Buy rating on Immunocore shares on ovarian cancer drug data - Investing.com India
Quarterly Metrics: Quick and Current Ratios for Immunocore Holdings plc ADR (IMCR) - The Dwinnex
Immunocore Holdings plc ADR (IMCR) is looking forward to a strong quarter - SETE News
Immunocore stock hits 52-week low at $32.84 amid market challenges - Investing.com
Ratios Revealed: Decoding Immunocore Holdings plc ADR (IMCR)’s Financial Health - The Dwinnex
Have you been able to find a good deal on Immunocore Holdings plc ADR’s shares? - US Post News
Immunocore Holdings plc (IMCR): Top ADR Stock According to Hedge Funds - Yahoo Finance UK
The growth track for Immunocore Holdings plc ADR (IMCR) has changed recently - SETE News
The Potential Rise in the Price of Sun Communities, Inc. (SUI) following insiders activity - Knox Daily
Insider Sale Alert: Terns Pharmaceuticals Inc [TERN] – Is it Time to sell? - Knox Daily
Immunocore Holdings plc ADR (IMCR) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Brookline Bancorp, Inc. (BRKL) after recent insider movements - Knox Daily
Immunocore Holdings plc ADR [IMCR] Shares Fall -4.18% on Thursday - Knox Daily
Financial Health Report: Immunocore Holdings plc ADR (IMCR)’s Ratios Tell a Tale - The Dwinnex
Insider Sale: President Brian Hole Sells Shares of Willis Lease Finance Corp (WLFC) - Yahoo Finance UK
IMCR’s 52-Week Rollercoaster: From $33.04 to $76.98 – What’s Next for Investors? - The InvestChronicle
Immunocore CFO to depart, company seeks replacement - Investing.com
IMCR’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Immunocore Holdings plc ADR [IMCR] Insider Activity: An Update for Investors - Knox Daily
Top 10 ADR Stocks To Buy According to Hedge Funds - Insider Monkey
Ratio Examination: Immunocore Holdings plc ADR (IMCR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Examining the Potential Price Growth of Immunocore Holdings plc ADR (IMCR) - Knox Daily
Cancer Immunotherapy Market Size Expected to Touch USD 530.2 Billion by 2034, With 14.2% CAGR Growth: Prophecy Market Insights - GlobeNewswire Inc.
South Korea Cancer Immunotherapy Market Size & Outlook, 2030 - Grand View Research
Brazil Cancer Immunotherapy Market Size & Outlook, 2030 - Grand View Research
Potential Price Increase for Immunocore Holdings plc ADR (IMCR) After Recent Insider Activity - Knox Daily
Mizuho backs Outperform rating for Immunocore stock despite PT cut - Investing.com
Earnings call: Immunocore reports robust growth for KIMMTRAK in Q2 - Investing.com India
It would be worthwhile to take a closer look at Immunocore Holdings plc ADR (IMCR) - US Post News
Insider Selling Buzz: Immunocore Holdings plc ADR [IMCR] CHIEF HR OFFICER St Leger Tina Amber sold 4,375 shares of the company – Knox Daily - Knox Daily
An Analysis of Immunocore Holdings plc ADR (IMCR)’s Potential Price Growth - Knox Daily
Trading Day Review: Immunocore Holdings plc ADR (IMCR) Loses Momentum, Closing at 38.87 - The Dwinnex
Prepare Yourself for Liftoff: Immunocore Holdings plc ADR (IMCR) - SETE News
Finanzdaten der Immunocore Holdings Plc Adr-Aktie (IMCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunocore Holdings Plc Adr-Aktie (IMCR) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
St Leger Tina Amber | CHIEF HR OFFICER |
Apr 01 '24 |
Sale |
64.06 |
4,375 |
280,262 |
0 |
Berman David M | HEAD OF R&D |
Feb 28 '24 |
Option Exercise |
17.46 |
36,509 |
637,447 |
36,509 |
Berman David M | HEAD OF R&D |
Feb 28 '24 |
Sale |
68.59 |
36,509 |
2,504,158 |
0 |
Berman David M | HEAD OF R&D |
Feb 27 '24 |
Option Exercise |
17.46 |
54,938 |
959,217 |
54,938 |
Berman David M | HEAD OF R&D |
Feb 26 '24 |
Option Exercise |
17.46 |
28,553 |
498,535 |
28,553 |
Berman David M | HEAD OF R&D |
Feb 27 '24 |
Sale |
70.86 |
54,938 |
3,893,030 |
0 |
Berman David M | HEAD OF R&D |
Feb 26 '24 |
Sale |
70.65 |
28,553 |
2,017,288 |
0 |
St Leger Tina Amber | Chief HR Officer |
Jan 03 '24 |
Option Exercise |
29.87 |
4,375 |
130,681 |
4,375 |
St Leger Tina Amber | Chief HR Officer |
Jan 03 '24 |
Sale |
69.89 |
4,375 |
305,781 |
0 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):